• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: None
• F protein gene engineering:
  • Type: Recombinant vector construction
  • Description: RSV F from the first (pre-N), second (N-P), third (P-M), and sixth (HN-L) genome positions is expressed in a recombinant vaccine vector rB/HPIV3 viruses (Liang et al., 2014).
  • Detailed Gene Information: Click Here.
• Preparation: rB/HPIV3 viruses expressing RSV F from the first (pre-N), second (N-P), third (P-M), and sixth (HN-L) genome positions (Liang et al., 2014),
• Immunization Route: Intramuscular injection (i.m.)

• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: None
• Antigen: G and F protein (Falsey et al., 2022)
• G gene engineering:
  • Type: Recombinant vector construction
  • Detailed Gene Information: Click Here.
• Preparation: bPIV3 as a virus vaccine vector with the introduction of the RSV attachment (G) and fusion (F) genes into the bPIV3 RNA genome(Haller et al., 2003)
• Immunization Route: Intramuscular injection (i.m.)

• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Hamster
• F protein gene engineering:
  • Type: Recombinant protein preparation
  • Detailed Gene Information: Click Here.
• Immunization Route: Intramuscular injection (i.m.)

Hamster Response

• Vaccination Protocol: The hamsters were inoculated intranasally with 0.1 ml containing 10^6 TCID50 of rB/HPIV3-RSV F virus or with 10*6 PFU of wt RSV (A2 strain) (Liang et al., 2014) .
• Challenge Protocol: Challenge was performed by intranasal infection with 106 PFU of RSV in 0.1 ml at 31 days after immunization(Liang et al., 2014)
• Efficacy: Each rB/HPIV3 vector induced a high titer of neutralizing antibodies in hamsters against RSV and HPIV3. Protection against RSV challenge was greater for position 2 than for position 6. Evaluation of insert stability suggested that RSV F is under selective pressure to be silenced during vector replication in vivo, but this was not exacerbated by a high level of RSV F expression and generally involved a small percentage of recovered vector (Liang et al., 2014)

Hamster Response

• Vaccination Protocol: Hamsters were infected intranasally with 1×106  p.f.u. r-bPIV3, bPIV3/RSV(I), RSV or placebo (Opti-MEM) in a 0·1 ml volume(Haller et al., 2003)
• Challenge Protocol: Animals were inoculated on day 21 intranasally with 1×106 p.f.u. of hPIV3 or RSV. (Haller et al., 2003)
• Efficacy: The recombinant virus expressed the RSV G and F proteins sufficiently to evoke a protective immune response in hamsters upon challenge with RSV or human PIV3 and to elicit RSV neutralizing and PIV3 haemagglutinin inhibition serum antibodies. In effect, a bivalent vaccine was produced that could protect vaccinees from RSV as well as PIV3(Haller et al., 2003)

Hamster Response

• Vaccination Protocol: The hamsters were vaccinated intranasally with 106 PFU of b/h PIV3, b/h PIV3/RSV, RSV A2, b/h PIV3/hMPV, hMPV/NL/1/00, or placebo medium in a 100-μl volume, (Tang et al., 2003)
• Challenge Protocol: Animals were challenged intranasally with 106 PFU of RSV or hPIV3 per animal on day 28 postvaccination. (Tang et al., 2003)
• Efficacy: Animals immunized with b/h PIV3/RSV were protected completely from hPIV3 and RSV infection. (Tang et al., 2003)